| Literature DB >> 31885466 |
Daiane Flores Dalla Lana1, Bruna Gerardon Batista1, Gabriella da Rosa Machado1, Mário Lettieri Teixeira2, Luís Flávio Souza de Oliveira3, Michel Mansur Machado3, Saulo Fernandes de Andrade4, William Lopes5, Marilene Henning Vainstein5, Alejandro Peixoto de Abreu Lima6, Enrique Pandolfi6, Edilma Elayne Silva7, Alexandre Meneghello Fuentefria1, Gustavo Pozza Silveira7.
Abstract
Development of new antimicrobial agents, capable of combating resistant and multidrug-resistant fungal and bacterial clinical strains, is necessary. This study presents the synthesis and antimicrobial screening of 42 2-substituted-1,4-benzenediols, being 10 novel compounds. In total, 23 compounds showed activity against fungi and/or bacteria. Benzenediol compounds 2, 5, 6, 8, 11, and 12 demonstrated broad spectrum antimicrobial actions, including resistant and multidrug-resistant species of dermatophytes (Trichophyton mentagrophytes), Candida spp. and the ESKAPE panel of bacteria. Minimum inhibitory concentrations of these compounds for fungi and bacterial strains ranged from 25 to 50 µg/ml and 8-128 µg/ml, respectively. The antifungal mechanism of action is related to the fungal cell wall of dermatophytes and membrane disruption to dermatophytes and yeasts, in the presence of compound 8. Specific structural changes, such as widespread thinning along the hyphae and yeast lysis, were observed by scanning electron microscopy. The effects of compound 8 on cell viability are dose-dependent; however they did not cause genotoxicity and mutagenicity in human leukocyte cells nor haemolysis. Moreover, the compounds were identified as nonirritant by the ex-vivo Hen's egg test-chorioallantoic membrane (HET-CAM). The furan-1,4-benzenediol compound 5 showed in vivo efficacy to combat S. aureus infection using embryonated chicken eggs. Therefore, the compounds 8, and 5 are promising as hits for the development of new antimicrobial drugs with reduced toxicity.Entities:
Keywords: 1,4-benzenediol derivatives; Antimicrobial activity; ESKAPE pathogens; Fungi; Mechanism of action; Toxicity
Year: 2019 PMID: 31885466 PMCID: PMC6921195 DOI: 10.1016/j.jsps.2019.09.003
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
MICs/MFCs (µg/ml) of 1,4-benzenediols derivatives against a panel of eight filamentous fungi and yeasts.
| Compound | Dermatophytes | |||||||
|---|---|---|---|---|---|---|---|---|
| MCA 01 | MGY 42 | TME 16 | TRU 45 | CA ATCC 18804 | CK 02 | CG 09 | CT 72A | |
| 1 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | 50/50 | 50/50 | 50/50 | 50/50 |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 7 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | 25/>50 | 25/>50 | 25/>50 | 25/>50 |
| 50/50 | 50/50 | 50/50 | 50/50 | 50/50 | 50/50 | 50/50 | 50/50 | |
| 50/50 | 50/50 | 50/50 | 50/50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| >50/>50 | >50/>50 | >50/>50 | >50/>50 | 50/50 | 50/50 | 50/50 | 50/50 | |
| 50/50 | 50/50 | 50/50 | 50/50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 50/>50 | 50/>50 | 50/>50 | 50/>50 | >50/>50 | >50/>50 | >50/>50 | >50/>50 | |
| 0.03 (S) | 0.03 (S) | 4 (R | 0.06 (S) | – | – | – | – | |
| 1 (S) | 1 (S) | >32 (R | 1 (S) | – | – | – | – | |
| 0.5 (S) | 1 (S) | 16 (R | 1 (S) | 0.25 (S) | 1 (S) | 0.5 (S) | 1 (S) | |
| – | – | – | – | 1 (S) | ≥ 64 (R) | 0.25 (DDS) | 2 (S) | |
| – | – | – | – | – | 1 (R) | >4 (R) | 1 (R) | |
| – | – | – | – | – | 0.5 (S) | >8 (R) | >8 (R) | |
| – | – | – | – | – | – | – | 2 (R) | |
Multidrug-resistant and resistant fungal isolates; MIC, minimal inhibitory concentration; MFC, minimal fungicidal concentration; MCA, Microsporum canis; MGY, Microsporumgypseum; TME, Trichophyton mentagrophytes; TRU, Trichophyton rubrum; CA, Candida albicans; CK, Candida krusei; CG, Candida glabrata; CT, Candida tropicalis. TBF, terbinafine; GSF, griseofulvin; KTC, ketoconazole; FLC, fluconazole; ITC, itraconazole; MCZ, miconazole; VRC, voriconazole; R, resistance; R*, resistance in the sense of reduced susceptibility compared to other strains; S, susceptible; DDS, dose-dependent susceptibility.
1,4-benzenodiols 3 and 12 showed antifungal activity at 50 µg/ml for Gibberella fujikuroi (F2) and Fusarium solani (F9), which are resistant to ITC and FLC (MICs > 128 µg/ml).
MICs (µg/ml) of 1,4-benzenediols derivatives against the Gram-positive strains S. aureus, E. faecalis and the Gram-negative strain E. coli.
| Compound | Bacteria | ||||
|---|---|---|---|---|---|
| >128 | 8 | 32 | 16 | >128 | |
| 64 | 8 | >128 | 16 | 32 | |
| >128 | 32 | >128 | >128 | >128 | |
| >128 | 32 | 8 | 32 | >128 | |
| >128 | 64 | 64 | 128 | >128 | |
| >128 | 64 | 32 | 8 | >128 | |
| >128 | >128 | 64 | 64 | >128 | |
| 128 | 64 | >128 | >128 | 64 | |
| 128 | 64 | 16 | 32 | 32 | |
| 8 | 8 | 64 | 16 | 8 | |
| 64 | 16 | 64 | 128 | >128 | |
| >128 | 64 | >128 | >128 | >128 | |
| >128 | 64 | 32 | >128 | >128 | |
| >128 | >128 | 8 | >128 | >128 | |
| >128 | 32 | 128 | 16 | 128 | |
| 16 | 64 | 8 | 8 | >128 | |
| >128 | 32 | 16 | 32 | >128 | |
| oxacilin | 0.5 | 2 | 16 | – | – |
| ampicilin | 1 | 1 | 1 | 1 | 4 |
Resistant to methicillin.
MICs (µg/ml) of 1,4-benzenediol derivatives against Gram-negative ESKAPE panel bacteria.
| Compound | Bacteria | ||||
|---|---|---|---|---|---|
| 64 | 32 | 64 | 64 | 128 | |
| 8 | >128 | >128 | >128 | >128 | |
| >128 | >128 | >128 | >128 | >128 | |
| 128 | 128 | 64 | 128 | 128 | |
| >128 | 1 | 2 | 2 | 1 | |
IOC: Instituto Oswaldo Cruz.
Ampicilin.
Gentamicin.
Imipinem.
Fig. 11,4-Benzenediol derivatives (1–12) presented in Table 1, Table 2, Table 3.
Fig. 21,4-Benzenediol derivatives (13–23) presented in Table 2, Table 3.
Fig. 3SEM images; (A) C. albicans without treatment, (B) C. albicans treated with ITC, (C) C. albicans treated with compound 8, (D) M. canis without treatment, (E) M. canis treated with TBF, and (F) M. canis treated with compound 8.
Fig. 4Epifluorescence microscopy. (A) C. albicans before adding the fluorescent probe the vinylfluoroquinoline-1,4-benzenediol 24; (B, C, D and E): C. albicans treated with 24. Picture taken after 5 s; (F) M. canis before adding 24; (G, H and I): M. canis treated with 24. Pictures were taken after 60 s, and (J) after 300 s.
Fig. 5Toxicological analysis; (a) cell viability, (b) micronucleus frequency, and (c) DNA damage effects of compound 8. Bars with the same letters indicate statistical similarity (ANOVA–Tukey’s test).
Fig. 6Macroscopic changes in infected embryonated eggs. Eggs were infected on the 4th developmental day. (A) Control, no treatment (unviable embryo; S. aureus (ATCC 25923)). (B) After treatment with the furan derivative, compound 5 (64 µg/ml) - viable embryo.